Management of behavioral problems in Alzheimer's disease
- PMID: 20096151
- DOI: 10.1017/S1041610209991505
Management of behavioral problems in Alzheimer's disease
Abstract
Alzheimer's disease (AD) is a complex progressive brain degenerative disorder that has effects on multiple cerebral systems. In addition to cognitive and functional decline, diverse behavioral changes manifest with increasing severity over time, presenting significant management challenges for caregivers and health care professionals. Almost all patients with AD are affected by neuropsychiatric symptoms at some point during their illness; in some cases, symptoms occur prior to diagnosis of the dementia syndrome. Further, behavioral factors have been identified, which may have their origins in particular neurobiological processes, and respond to particular management strategies. Improved clarification of causes, triggers, and presentation of neuropsychiatric symptoms will guide both research and clinical decision-making. Measurement of neuropsychiatric symptoms in AD is most commonly by means of the Neuropsychiatric Inventory; its utility and future development are discussed, as are the limitations and difficulties encountered when quantifying behavioral responses in clinical trials. Evidence from clinical trials of both non-pharmacological and pharmacological treatments, and from neurobiological studies, provides a range of management options that can be tailored to individual needs. We suggest that non-pharmacological interventions (including psychosocial/psychological counseling, interpersonal management and environmental management) should be attempted first, followed by the least harmful medication for the shortest time possible. Pharmacological treatment options, such as antipsychotics, antidepressants, anticonvulsants, cholinesterase inhibitors and memantine, need careful consideration of the benefits and limitations of each drug class.
Similar articles
-
Management of agitation and aggression associated with Alzheimer's disease: controversies and possible solutions.Curr Opin Psychiatry. 2009 Nov;22(6):532-40. doi: 10.1097/YCO.0b013e32833111f9. Curr Opin Psychiatry. 2009. PMID: 19696673 Review.
-
[Treatment of neuropsychiatric symptoms in Alzheimer's disease].Rev Neurol. 2002 Nov 1-15;35(9):846-50. Rev Neurol. 2002. PMID: 12436383 Spanish.
-
The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.Postgrad Med. 2005 Jan;Spec No:6-22. Postgrad Med. 2005. PMID: 17203561
-
Innovations: geriatric psychiatry: diagnosis and treatment of neuropsychiatric symptoms in Alzheimer's disease.Psychiatr Serv. 2006 May;57(5):617-9. doi: 10.1176/ps.2006.57.5.617. Psychiatr Serv. 2006. PMID: 16675752
-
Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmas.World J Biol Psychiatry. 2008;9(1):69-75. doi: 10.1080/15622970701568412. World J Biol Psychiatry. 2008. PMID: 17886162 Review.
Cited by
-
Application of behavior-based ergonomics therapies to improve quality of life and reduce medication usage for Alzheimer's/dementia residents.Am J Alzheimers Dis Other Demen. 2013 Feb;28(1):35-41. doi: 10.1177/1533317512467678. Epub 2012 Nov 29. Am J Alzheimers Dis Other Demen. 2013. PMID: 23196404 Free PMC article. Clinical Trial.
-
The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence.CNS Drugs. 2012 Aug 1;26(8):663-90. doi: 10.2165/11634390-000000000-00000. CNS Drugs. 2012. PMID: 22784018 Review.
-
Neurobiology of delusions in Alzheimer's disease.Curr Psychiatry Rep. 2011 Jun;13(3):211-8. doi: 10.1007/s11920-011-0195-1. Curr Psychiatry Rep. 2011. PMID: 21404128 Review.
-
Association of the US Food and Drug Administration Antipsychotic Drug Boxed Warning With Medication Use and Health Outcomes in Elderly Patients With Dementia.JAMA Netw Open. 2020 Apr 1;3(4):e203630. doi: 10.1001/jamanetworkopen.2020.3630. JAMA Netw Open. 2020. PMID: 32343351 Free PMC article.
-
Tablet Splitting in Elderly Patients with Dementia: The Case of Quetiapine.Pharmaceutics. 2021 Sep 20;13(9):1523. doi: 10.3390/pharmaceutics13091523. Pharmaceutics. 2021. PMID: 34575599 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical